FDA advisory panel discusses droperidol concerns.
Donna
D
Young
D026683:Advisory Committees; D004329:Droperidol / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004348:Drug Labeling; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced / Q000453:epidemiology; D011358:Product Surveillance, Postmarketing / Q000592:standards; D014481:United States; D014486:United States Food and Drug Administration
D004329:Droperidol